Toward new standards for noninvasive measuring of portal pressure?
Søren Møller – 24 December 2015
Genetic variation in STAT4 predicts response to interferon‐α therapy for hepatitis B e antigen‐positive chronic hepatitis B
De‐Ke Jiang, Xiaopan Wu, Ji Qian, Xiao‐Pin Ma, Jingmin Yang, Zhuo Li, Runhua Wang, Li Sun, Fang Liu, Pengyin Zhang, Xilin Zhu, Jia Wu, Kangmei Chen, Carly Conran, S. Lilly Zheng, Daru Lu, Long Yu, Ying Liu, Jianfeng Xu – 24 December 2015 – Interferon (IFN)‐α is a first‐line therapy for chronic hepatitis B (CHB) patients but only initiates a response in a minority of patients. A genetic variant, rs7574865 in STAT4, was recently reported to be associated with risk of developing CHB and hepatitis B virus‐related hepatocellular carcinoma.
Do ITPA gene variants provide insight to detecting patients infected with HCV 2/1 recombinant strains?
Enrico Galmozzi, Roberta D'Ambrosio – 24 December 2015
CD14+ regulatory dendritic cells in patients with hepatocellular carcinoma and cirrhosis
Shiroh Tanoue, David E. Kaplan – 24 December 2015
Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: A phase 3 study (OPTIMIST‐2)
Eric Lawitz, Gary Matusow, Edwin DeJesus, Eric M. Yoshida, Franco Felizarta, Reem Ghalib, Eliot Godofsky, Robert W. Herring, Gary Poleynard, Aasim Sheikh, Hillel Tobias, Marcelo Kugelmas, Ronald Kalmeijer, Monika Peeters, Oliver Lenz, Bart Fevery, Guy De La Rosa, Jane Scott, Rekha Sinha, James Witek – 24 December 2015 – Hepatitis C virus (HCV)–infected patients with cirrhosis are historically a difficult‐to‐treat population and are at risk of hepatic decompensation.
Reply
Lesley De Pietri, Marcello Bianchini, Guadalupe Garcia‐Tsao, Erica Villa – 24 December 2015
Prediction of bleeding in cirrhosis patients: Is the forecast any clearer?
Nicolas M. Intagliata, Stephen H. Caldwell, Robert J. Porte, Ton Lisman – 24 December 2015
Safety and efficacy of ledipasvir/sofosbuvir for the treatment of genotype 1 hepatitis C in subjects aged 65 years or older
Sammy Saab, Sarah H. Park, Masashi Mizokami, Masao Omata, Alessandra Mangia, Ed Eggleton, Yanni Zhu, Steven J. Knox, Phil Pang, Mani Subramanian, Kris Kowdley, Nezam H. Afdhal – 24 December 2015 – Elderly subjects have been historically underrepresented in clinical trials involving antiviral hepatitis C therapies. The aim of this analysis was to retrospectively evaluate the safety and efficacy of ledipasvir/sofosbuvir (LDV/SOF) by age groups of <65 years versus ≥65 years among subjects enrolled in phase 3 trials.
Squaring the circle of selection and allocation in liver transplantation for HCC: An adaptive approach
Vincenzo Mazzaferro – 24 December 2015
Histidine‐rich glycoprotein promotes macrophage activation and inflammation in chronic liver disease
Matthias Bartneck, Viktor Fech, Josef Ehling, Olivier Govaere, Klaudia Theresa Warzecha, Kanishka Hittatiya, Mihael Vucur, Jérémie Gautheron, Tom Luedde, Christian Trautwein, Twan Lammers, Tania Roskams, Willi Jahnen‐Dechent, Frank Tacke – 23 December 2015 – Pathogen‐ and injury‐related danger signals as well as cytokines released by immune cells influence the functional differentiation of macrophages in chronic inflammation.